Guardant Health Inc (MIL:1GH) Share Price

Company Profile

Business description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Contact
3100 Hanover Street
Palo AltoCA94304
USA
T: +1 855 698-8887
E: [email protected]
https://www.guardanthealth.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,021

Recommended

Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.

Joseph Taylor | 03 August 2025

We were wrong when we thought last quarter would be hard to top.

Dan Romanoff, CPA | 31 July 2025

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,917.10	81.90	-0.91%
CAC 40	7,546.16	225.81	-2.91%
DAX 40	23,425.97	639.50	-2.66%
Dow JONES (US)	43,588.58	542.40	-1.23%
FTSE 100	9,068.58	64.23	-0.70%
HKSE	24,507.81	265.52	-1.07%
NASDAQ	20,650.13	472.31	-2.24%
Nikkei 225	40,799.60	270.22	-0.66%
NZX 50 Index	12,729.40	94.34	-0.74%
S&P 500	6,238.01	101.38	-1.60%
S&P/ASX 200	8,662.00	80.80	-0.92%
SSE Composite Index	3,559.95	13.26	-0.37%